1. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialResearch in context
- Author
-
Jeffrey L. Bennett, Orhan Aktas, William A. Rees, Michael A. Smith, Michele Gunsior, Li Yan, Dewei She, Daniel Cimbora, Sean J. Pittock, Brian G. Weinshenker, Friedemann Paul, Romain Marignier, Dean Wingerchuk, Gary Cutter, Ari Green, Hans-Peter Hartung, Ho Jin Kim, Kazuo Fujihara, Michael Levy, Eliezer Katz, and Bruce A.C. Cree
- Subjects
Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder ,Devic disease ,Anti-CD19 monoclonal antibody ,B-cell suppression ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Inebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies. The relationship between B-cell, plasma-cell (PC), and immunoglobulin depletion with longitudinal reductions in NMOSD activity after inebilizumab treatment was characterised post hoc in an exploratory analysis from the N-MOmentum study (NCT02200770). Methods: Peripheral blood CD20+ B cells, PC gene signature, and immunoglobulin levels were assessed throughout N-MOmentum (follow-up ≥2.5 years); correlations with clinical metrics and magnetic resonance imaging (MRI) lesion activity were assessed. Findings: Inebilizumab induced durable B-cell and PC depletion within 1 week versus placebo. Although no association was observed between B-cell counts at time of attack and NMOSD activity, depth of B-cell depletion after the first dosing period correlated with clinical outcomes. All participants receiving inebilizumab demonstrated a robust long-term therapeutic response, and participants with ≤4 cells/μL after the first 6-month dosing interval had persistently deeper B-cell depletion, lower annualised attack rates (estimated rate [95% CI]: 0.034 [0.024–0.04] vs 0.086 [0.056–0.12]; p = 0.045), fewer new/enlarging T2 MRI lesions (0.49 [0.43–0.56] vs 1.36 [1.12–1.61]; p
- Published
- 2022
- Full Text
- View/download PDF